A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. (Q47578779)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

title

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

3

Julie M Vose

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

1

Bruce D Cheson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Andres Lopez-Hernandez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

Amanda L Seiz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

Anne T Keating

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

Setareh Shamsili

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

Kyriakos P Papadopoulos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

English

0 references

publication date

17 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

3128-3134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

14 January 2020

cites work

1 reference

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

Structural basis for phosphoserine-proline recognition by group IV WW domains

21 January 2018

1 reference

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts

21 January 2018

1 reference

Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors

21 January 2018

1 reference

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

Expression of the NF-κB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively

21 January 2018

1 reference

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26510

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22006123 AND SRC:MED&resulttype=core&format=json

release_5l7nouhlrzbznejmgl3nseifne

14 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5l7nouhlrzbznejmgl3nseifne

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference